Sara Vaz-Pereira

Prof. Dr. Sara Vaz-Pereira

Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2014 in American Journal of Ophthalmology
Verified
Journal Article
Closed access
Gabriella De SalvoGabriella De Salvo
Gabriella De Salvo
Sara Vaz-PereiraSara Vaz-Pereira
Sara Vaz-Pereira
PKPearse Keane
Pearse Keane
ATAdnan Tufail
Adnan Tufail
GLGerald Liew
Gerald Liew

1 February 2018 in Cytokine & Growth Factor Reviews
Verified
Journal Article
Closed access
JMJoana Mesquita
Joana Mesquita
JCJoão Paulo Castro-De-Sousa
João Paulo Castro-De-Sousa
Sara Vaz-PereiraSara Vaz-Pereira
Sara Vaz-Pereira
ANArminda Neves
Arminda Neves
Luis PassarinhaLuis Passarinha
Luis Passarinha
Cândida Teixeira TomazCândida Teixeira Tomaz
Cândida Teixeira Tomaz

29 June 2020 in International Journal of Retina and Vitreous
Verified
Journal Article
Open access
PDF file
Sara Vaz-PereiraSara Vaz-Pereira
Sara Vaz-Pereira
TMTiago Morais-Sarmento
Tiago Morais-Sarmento
RMRaquel Esteves Marques
Raquel Esteves Marques
Background: Diabetic retinopathy (DR) is a leading cause of blindness due to diabetic macular edema (DME) or complications of proliferative diabetic retinopathy (PDR). Optical coherence tomography (OCT) is a noninvasive imaging technique well established for DME but less used to assess neovascularization in PDR. Developments in OCT imaging and the introduction of OCT angiography (OCTA) have shown significant potential in PDR. Objectives: To describe the tomographic features of PDR, namely of neovascularization, both of the optic disc (NVD) and elsewhere (NVE), intraretinal microvascular abnormalities (IRMA), retinal nonperfusion areas (NPA), status of the posterior vitreous, vitreoschisis and vitreous and subhyaloid/sub-ILM hemorrhages. Data sources: Electronic database search on PubMed and EMBASE, last run on December 19th 2019. Study eligibility criteria, participants and interventions: Publications assessing OCT and/or OCTA findings in PDR patients. All study designs were allowed except for case-reports, conference proceedings and letters. Study appraisal: Newcastle–Ottawa Scale for observational studies was used for purposes of risk of bias assessment. Results: From the 1300 studies identified, 283 proceeded to full-text assessment and 60 were included in this comprehensive review. OCT was useful in detecting NVD and NVE, such as in characterizing disease activity and response to laser and/or anti-VEGF therapies. The absence of posterior vitreous detachment seemed determinant for neovascular growth, with the posterior hyaloid acting as a scaffold. OCTA allowed a more detailed characterization of the neovascular complexes, associated NPA and disease activity, allowing the quantification of neovessel area and flow index. However, changes in OCTA blood flow signal following local therapies did not necessarily correlate with structural regression. Widefield and ultra-widefield OCTA were highly sensitive in the detection of PDR, adding value to disease staging and monitoring. Compared to fluorescein angiography, OCTA was more sensitive in detecting microvascular changes indicating disease progression. Limitations: Publication languages were restricted. Most included studies were observational and non-comparative. Risk of bias regarding case representativeness. Conclusions: OCT-based retinal imaging technologies are advancing rapidly and the trend is to be noninvasive and wide-field. OCT has proven invaluable in diagnosing, staging and management of proliferative diabetic disease with daily application in clinical and surgical practices.

1 July 2017 in Retina
Verified
Journal Article
Closed access
Sara Vaz-PereiraSara Vaz-Pereira
Sara Vaz-Pereira
KDKunal K. Dansingani
Kunal K. Dansingani
KCKevin C. Chen
Kevin C. Chen
MCMichael J. Cooney
Michael J. Cooney
JKJames M. Klancnik
James M. Klancnik
MEMichael Engelbert
Michael Engelbert
Purpose: To describe anatomical relationships of retinal neovascular complexes (NVCs) and the posterior vitreous in proliferative diabetic retinopathy using spectral domain optical coherence tomography. Methods: Cross-sectional study. Neovascular complexes were imaged using spectral domain optical coherence tomography in 51 eyes of 37 patients. The relationship of NVCs to the posterior vitreous cortex and posterior vitreous spaces, such as the premacular bursa, prevascular vitreous fissures, and perimacular cisterns, was analyzed. Results: In the 77 NVCs evaluated, 61 (79%) had grown along the outer surface of the posterior hyaloid face, and vitreoschisis was present in 37 (48%). The “wolf's jaw” configuration was present in 9% and resulted from NVC arising from the arcades and proliferating along the posterior hyaloid face. By contrast, NVCs that invaded the bursa originated from smaller venous tributaries more distant from the arcades. The premacular bursa and prevascular vitreous fissure/perimacular cistern were invaded infrequently, respectively, in 15% and 38% (P = 0.137). Conclusion: Tomographic analysis of diabetic NVCs showed that most NVCs arise and grow along the posterior hyaloid face and that vitreoschisis is more prevalent than what has been found in ultrasound studies. The wolf's jaw configuration does not seem to result from the invasion of the bursa, as previously suggested.

1 July 2019 in Ophthalmology Retina
Verified
Journal Article
Open access
JGJustus G. Garweg
Justus G. Garweg
JSJana Stefanickova
Jana Stefanickova
CHCarel Hoyng
Carel Hoyng
TSThomas Schmelter
Thomas Schmelter
TNTobias Niesen
Tobias Niesen
Tomasz ZarnowskiTomasz Zarnowski
Tomasz Zarnowski
To examine vision-related quality of life in patients with diabetic macular edema (DME) treated with intravitreal aflibercept (EYLEA, Regeneron Pharmaceuticals, Inc, Tarrytown, NY). AQUA was a multicenter, open-label, single-arm, phase 4 study. Adults 18 years of age or older with type 1 or 2 diabetes mellitus and DME. Patients received intravitreal aflibercept 2 mg every 8 weeks for 52 weeks, after 5 initial doses every 4 weeks. The primary outcome was the change in 25-item National Eye Institute Visual Function Questionnaire (NEI VFQ-25) total score from baseline to week 52. Secondary outcomes included the change in NEI VFQ-25 near and distant activities subscale scores, best-corrected visual acuity (BCVA; Early Treatment Diabetic Retinopathy Study [ETDRS] letters), and central retinal thickness (CRT) from baseline to week 52. Change in NEI VFQ-25 score at week 52 for better-seeing eyes (BSEs) and worse-seeing eyes (WSEs) also was evaluated. A total of 553 patients comprised the full analysis set, and 560 patients comprised the safety analysis set. At baseline, the mean NEI VFQ-25 total score was 70.12, mean BCVA was 61.5 ETDRS letters, and mean CRT was 464.81 μm. A mean of 8.8 injections were administered over 52 weeks. At week 52, the mean improvement from baseline in the NEI VFQ-25 total score was +6.11 (standard deviation [SD], 11.46); the corresponding improvements in near and distant activities were +11.37 (SD, 18.01) and +7.33 (SD, 17.32), respectively. Similarly, improvements in patients whose BSE and WSE were treated were 7.74 (SD, 13.59) and 5.48 (SD, 9.70), respectively. At week 52, mean change in BCVA was +10.0 ETDRS letters (SD, 8.0 ETDRS letters), and mean change in CRT was -175.38 μm (SD, 132.62 μm). Overall, 53.6% of patients reported treatment-emergent adverse events (TEAEs), of whom 26.8% experienced an ocular TEAE in the study eye. The most common serious ocular TEAE was endophthalmitis (0.5% [n = 3]). Five deaths (0.9%) were reported, but were not considered treatment related. Intravitreal aflibercept was associated with clinically meaningful improvements in NEI VFQ-25 total score over 52 weeks in patients with DME; these were even more pronounced for near than for distant activities. Adverse events were consistent with the known safety profile of intravitreal aflibercept.

4 March 2018 in Growth Factors
Verified
Journal Article
Closed access
JMJoana Mesquita
Joana Mesquita
JCJoão Paulo Castro-De-Sousa
João Paulo Castro-De-Sousa
Sara Vaz-PereiraSara Vaz-Pereira
Sara Vaz-Pereira
ANArminda Neves
Arminda Neves
Luis PassarinhaLuis Passarinha
Luis Passarinha
Cândida Teixeira TomazCândida Teixeira Tomaz
Cândida Teixeira Tomaz
VEGF-A and VEGF-B are proangiogenic and key regulating factors for blood vessel growth. This study aims to compare VEGF-A and VEGF-B levels in the serum and vitreous of patients with neovascular pathology versus non-neovascular pathology. Our findings showed vitreous VEGF-A and VEGF-B levels increased in patients with neovascular disease, with higher levels of VEGF-A compared to VEGF-B (p ≤ .05). In the diabetic retinopathy (DR) group, higher vitreous VEGF-A or VEGF-B were found in proliferative diabetic retinopathy (PDR) than in non-PDR. The strong correlation between VEGF-A and VEGF-B demonstrates a simultaneous pathological increase of cytokines (p < .001), suggesting besides VEGF-A, VEGF-B is another contributor to ocular pathologies involving angiogenesis. There was no correlation between vitreous and serum VEGF-A or VEGF-B; however, a correlation between vitreous (VEGF-A or VEGF-B) and macular volume (p < .05) in DR patients was found. Targeting VEGF-A and VEGF-B in macular and retinal vascular diseases, involving neovascularization, may improve treatment outcomes.